Coeliac disease (CoD) is a chronic inflammatory intestinal disorder caused by dietary gluten proteins (prolamines) from cereals in genetically predisposed individuals. The disease is manifested by a lesion which ranges from a complete transformation of the mucosa with villus atrophy and crypt cell hyperplasia to the infiltration by lymphocytes of the epithelium and lamina propria. Gluten is uniquely resistant to gastrointestinal digestion, and gluten fragments accumulate in the intestine where they trigger two distinct immune responses, mediated by the innate and adaptive immunity, and both contribute to the pathogenesis of CoD. 1 2 Although HLA-DQ2/8 is the major predisposing factor, other non-HLA genes, some of them related to the innate response, 3 and/or environmental factors might contribute to the development of the disease in a small group of DQ2+ individuals.
Immunostimulatory peptides, as assessed by using lymphocyte-based systems, have been identified in gliadin and glutenins from wheat gluten, and homologues from barley and rye. All peptides which are stimulatory when tested in vitro are also harmful in vivo. The best known is the immunogenic peptide p57-89 (33mer) from a-gliadin, which is the preferred substrate for tissue transglutaminase (TGt) and once deaminated becomes a potent activator of gluten-specific DQ2-restricted CD4+ T cells from patients with CoD, characterised by interferon g (IFNg) production.
Other peptides, like p31-43/49 from a-gliadin, are toxic in vivo and in vitro, and have a direct effect on the epithelium, but do not stimulate gluten-specific T cells from patients with CoD. 4 These peptides induce enterocyte expression of both interleukin 15 (IL15) and the non-classical major histocompatibility complex (MHC) class I chain-related A (MICA) molecules and HLA-E, as well as IL15 production by lamina propria mononuclear cells, which in turn promotes intraepithelial proliferation and expression of the receptors NKG2D and CD94, leading to the target killing of MICA-expressing enterocytes. 1 2 The molecular basis of the adaptive DQ-restricted immune response to gluten is well understood. Less clear is how luminal gliadin peptides cross the intestinal epithelium and initiate the specific response mediated by lamina propria CD4+ T cells, and how these gluten-specific T cells control the expansion and activation of intraepithelial T lymphocytes. Moreover, little is known about the role of enterocytes in the uptake and processing of gliadin peptides, how these peptides activate innate immunity in the early stages of intestinal inflammation, and why these effects are only observed in HLA-DQ2+ patients. No specific receptor has been described for p31-43, though it has been reported that this peptide may potentiate the effect of epidermal growth factor by interference in the inactivation of its receptor, 5 or that it may induce the early upregulation of TGt in the epithelium by a mechanism still unknown. 6 The major route of transepithelial passage of gliadin peptides is by transcytosis, though the underlying mechanisms are not yet clear. 2 In active CoD, the apical-to-basal transport is increased, in an IFNg-dependent manner, but intraepithelial processing is also altered, allowing intact and/or partially degraded toxic and immunogenic peptides to enter the mucosa. 7 8 This depends on the intestinal inflammation of untreated CoD, which may also increase the passive paracellular diffusion of peptides through opened epithelial tight junctions via 'MyD88-dependent' release of zonulin. 9 Other receptor-mediated mechanisms may contribute to the translocation of intact gliadin peptides to the lamina propria, by using a protected pathway driven by gluten-specific secretory IgA via transferrin receptor CD71, 10 or involving myeloid dendritic cells expressing both HLA-DQ and surface TGt.
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In this issue of Gut, the papers by Luciani et al 12 (see page 311) and by Zimmer et al 13 (see page 300) focus on some of the unsolved questions of CoD pathogenesis. By using epithelial cell lines and human duodenal biopsies, the authors analysed the epithelial uptake and processing of gliadin peptides via intracellular compartments, which result in the activation of new signalling pathways of mucosal inflammation, 12 and different routes of antigen presentation. 13 These papers describe two different pathways of endocytosis and delivery of gliadin peptides to paranuclear vesicles which may be relevant in the initial steps of the development of the disease, though the mechanisms responsible for the segregation and/or accumulation of these peptides remain obscure. Rather than a primary epithelial defect in patients with CoD, this is probably due to the intrinsic properties of p31-43/49, because other peptides are removed from the vesicular system.
In the study by Luciani et al, 12 all peptides can reach the late endosomes and lysosomes, but p31-43 (unlike other peptides) is retained in the latter where it generates a pro-oxidative environment which induces TGt activation and degradation of peroxisome proliferator-activated receptor (PPAR) g, a modulator of intestinal inflammation. This mechanism might explain why patients with CoD relapse after gluten reintroduction, even when signs of inflammation are absent. The early effects of gliadin might be relatively common, 14 but signalling pathways may undergo downregulatory control in non-CoD individuals. However, in HLA-DQ2+ patients, the innate related signal may be amplified by other factors: expression of cytokine-related genes, 3 TGt activation and PPARg degradation, 12 or high IL15Ra expression, 15 leading to the triggering of an adaptive immune response mediated by gluten-reactive CD4 T cells.
Zimmer et al 13 confirmed that both toxic and immunogenic peptides are internalised by the enterocytes, but they follow different endocytotic pathways, as shown by p31-49 which bypasses HLA-DR+ late endosomes and escapes antigen presentation at the basolateral membrane, though we do not know the fate of these peptides: are they translocated by a protected pathway, or degraded in endosomes? The authors hypothesised that HLA-DR+ enterocytes generate a tolerogenic effect in contrast to the immunostimulatory effect mediated by HLA-DQ+ lamina propria dendritic cells.
Still, these mechanisms have to be validated in vivo, and further studies should evaluate the uptake and processing of both toxic and immunogenic gliadin peptides by normal and inflamed mucosa (or in the early and late stages of the disease). Moreover, its specificity to the CoD intestine has to be confirmed, and it would be interesting to know how early inflammation is controlled by non-CoD individuals: is this related to HLA/non-HLA genes, or to other local or environmental factors? These results open the way for alternative therapies based on the use of antioxidants, TGt inhibitors (and PPARg modulators), or the re-induction of tolerance.
